

HALAVEN[®] CONVERSATIONS

Your guide to speaking with your
health care team about HALAVEN

**To understand who HALAVEN is for and Important Safety Information,
please see pages 4 and 5 of this guide.**

These are some questions that may help you better understand your treatment as you talk to your doctor or nurse about HALAVEN. You can print out and take them with you to your next appointment. There is space below each question to take notes during your discussion.

Setting goals

My goal of treatment is: _____

How can HALAVEN help me reach my goal?

How does HALAVEN work?

Starting HALAVEN®

How will I receive HALAVEN?

How often will I get HALAVEN treatment?

How long will I be on HALAVEN?

Where will I get my HALAVEN treatment?

Understanding side effects

What are the most common side effects I should look out for?

What are the most serious side effects I should look out for?

When should I call my health care team about side effects?

What can I do to help manage these side effects?

Please see all Important Safety Information on pages 4 and 5, full Prescribing Information, and Patient Information.



Support along your treatment journey

What resources are available to me while I am on HALAVEN?

What support groups can I join while I am on HALAVEN?

Whom can I contact for information about financial assistance for HALAVEN?

Additional questions

Write any other questions you have here:

For more information about HALAVEN, please read the *Commonly Asked Questions About HALAVEN* Brochure in the Helpful Resources section of www.halaven.com

Please see all Important Safety Information on pages 4 and 5, full Prescribing Information, and Patient Information.



Who is HALAVEN® for?

HALAVEN is a prescription medicine used to treat patients with metastatic breast cancer. HALAVEN is for patients who have already received at least 2 other types of anticancer medicines for their breast cancer once it has spread to other parts of the body. Previous therapy should have included an anthracycline and a taxane for either early or advanced breast cancer.

What safety information do I need to know about HALAVEN?

Neutropenia (Decreased White Blood Cells)

- Your health care provider should do a blood test to monitor your blood cells before you receive each dose of HALAVEN, and should monitor you more often if you develop lower white blood cells
- If you develop severe neutropenia lasting longer than 7 days or neutropenia with a fever, your next dose of HALAVEN should be delayed and reduced. In a clinical trial, severe neutropenia occurred in 57% of patients who received HALAVEN and lasted more than 1 week in 12% of patients
- Neutropenia with a fever occurred in 5% of patients; 2 patients died from complications of neutropenia with a fever
- Neutropenia with a fever can result in serious infections that could lead to hospitalization or death. Call your health care provider immediately if you have any of the following symptoms: fever (temperature above 100.5°F), chills, coughing, and burning or pain when you urinate

Peripheral Neuropathy (Nerve Problems)

- HALAVEN can cause numbness, tingling, or burning in your hands and feet (peripheral neuropathy). You should be monitored closely for signs of neuropathy. If you develop severe neuropathy, treatment with HALAVEN should be delayed until the neuropathy improves and the next dose of HALAVEN should be reduced
- Severe peripheral neuropathy occurred in 8% of patients who received HALAVEN. Neuropathy lasting more than 1 year occurred in 5% of patients. Twenty-two percent of patients developed a new or worsening neuropathy that had not recovered after an average of 269 days
- Peripheral neuropathy was the most common side effect that caused patients to stop taking HALAVEN

Please see additional Important Safety Information on the next page, full Prescribing Information, and Patient Information.



Pregnancy and Nursing

- HALAVEN may harm your unborn baby. Avoid becoming pregnant while you are receiving HALAVEN. Tell your health care provider right away if you become pregnant or think you are pregnant while you are receiving HALAVEN
- It is not known if HALAVEN passes into your breast milk. You and your health care provider should decide if you will take HALAVEN or breast-feed. You should not do both

QT Prolongation (Heartbeat Changes)

- HALAVEN can cause changes in your heartbeat. This can cause irregular heartbeats that may lead to death
- Before you receive HALAVEN, tell your health care provider if you have heart problems, including a problem called “congenital long QT syndrome”
- Your health care provider will decide if you need heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to watch for this problem

Pre-existing Liver and/or Kidney Problems

- Before you receive HALAVEN, tell your health care provider if you have liver or kidney problems. A lower starting dose of HALAVEN is recommended in patients with mild or moderate liver problems, and/or moderate or severe kidney problems

Most Common Side Effects

- The most common side effects reported in $\geq 25\%$ of patients receiving HALAVEN were low white blood cells; low red blood cells; weakness/tiredness; hair loss; numbness, tingling, or burning in the hands and feet; nausea; and constipation
- The most common serious side effects reported in patients receiving HALAVEN were neutropenia with or without a fever

Please see additional Important Safety Information on the previous page, full Prescribing Information, and Patient Information.



HALAVEN® is a registered trademark used by Eisai Inc.
under license from Eisai R&D Management Co., Ltd.
© 2021 Eisai Inc. March 2021 HALA-US3514

